January 10, 2017

Beijing Mabworks Company Completes $39 Million Series B Funding

Beijing Mabworks Biotech, a gene engineering mAb company, raised $39 million for a Series B round, led by Shenzhen GTJA Investment Group. GTJA is a healthcare focused investment firm. Founded in 2003, Mabworks is working on ZMapp, an Ebola treatment developed by San Diego’s MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech’s Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

EVENTS

WuXi Executive Breakfast in Basel: The Most Important Innovation in Drug R&D May Be How the Industry Works Together

Reflections from the WuXi Executive Breakfast at Swiss Biotech Day

May 11, 2026

READ MORE

FEATURED

Meet Marco Glucini: Every Project Is Its Own Expedition

A mountain offers no shortcuts. The destination may be visible from the outset, but the route is rarely straightforward. There are steep sections, unexpected obstacles, changing conditions and moments when progress depends on careful steps, experience and trust in the people climbing alongside you. For Marco Glucini, Senior Business Development Manager at WuXi STA, that is also the best way to describe pharmaceutical development...

August 10, 2026

Some careers begin with a plan. Others begin with a question. For Jacob Mandell, Associate Director of Business Development at WuXi AppTec, it was the latter that quietly shaped everything that followed. By late June, he’ll be celebrating his 5th year with WuXi AppTec...

July 24, 2026

Across complex therapeutic areas, innovators are applying an expanding range of new modalities, from antibody-drug conjugates (ADCs) and bispecific antibodies to peptides, oligonucleotides, and other advanced formats. Yet as the therapeutic toolbox expands, one principle remains central: modality should follow biology...

May 28, 2026

READ MORE